| Outcome Measures: |
Primary: Measure: Pharmacokinetics of aliskiren: Area under the concentration-time curve from time zero to 48- hour post-dose (AUC(0-48hrs)), from time zero to the last measurable concentration sampling time (AUClast), from time zero to infinity (AUCinf), Pharmacokinetics (concentrations of aliskiren in blood and urine) of a single dose of aliskiren in End Stage Renal Disease (ESRD) patients on hemodialysis and matched healthy subjects was analyzed., 48 hours (period 1) , 1 hour (Period 2)|Pharmacokinetics of aliskiren: Maximum (peak) observed blood and urine drug concentration (Cmax) after single dose administration, Pharmacokinetics (concentrations of aliskiren in blood and urine) of a single dose of aliskiren in End Stage Renal Disease (ESRD) patients on hemodialysis and matched healthy subjects was analyzed., 48 hours (period 1) , 1 hour (Period 2)|Pharmacokinetics of aliskiren: Time to reach maximum (peak) blood and urine drug concentration (Tmax) and elimination half-life (t1/2) after single dose administration, Pharmacokinetics (concentrations of aliskiren in blood and urine) of a single dose of aliskiren in End Stage Renal Disease (ESRD) patients on hemodialysis and matched healthy subjects was analyzed., 48 hours (period 1) , 1 hour (Period 2) | Secondary: Effect of timing of hemodialysis on the PK of aliskiren in End Stage Renal Disease (ESRD) patients, 48 hrs (Period 1), 1 hr (Period 2)|Number of patients with adverse events, serious adverse events and death, maximum 30 days
|
